CMFRI develops anti-obesity medicine from marine organism Business Standard dated 16th February 2017

CMFRI, Library (2017) CMFRI develops anti-obesity medicine from marine organism Business Standard dated 16th February 2017. Business Standard.

[img] Text
Business Standard_16-02-2017.pdf

Download (113kB)
Official URL: http://www.business-standard.com/article/news-ians...
Related URLs:

    Abstract

    Kochi-headquartered Central Marine Fisheries Research Institute (CMFRI) has developed an anti-obesity nutraceutical from seaweeds, the institute said on Wednesday. Kerala Governor Justice P Sathasivam will release the product during the CMFRI Platinum Jubilee celebrations inaugural function on Saturday, it said in a statement. CMFRI scientists prepared the product named CadalminTM Antihypercholesterolemic extract (CadalminTM ACe) from seaweeds which are commonly available in the Indian coastal waters and are known for their extraordinary medicinal properties. Kajal Chakraborty, Senior Scientist in Marine Biotechnology Division of CMFRI, who developed the product, said CadalminTM Antihypercholesterolemic extract can be administered to regulate clinical indicators leading to dyslipidemia or obesity, total adipose tissue and visceral fat, triglycerides besides cholesterol.

    Item Type: Other
    Uncontrolled Keywords: Newspaper; News; CMFRI in Media
    Subjects: CMFRI News Clippings
    Divisions: Library & Documentation
    Depositing User: Arun Surendran
    Date Deposited: 16 Feb 2017 10:03
    Last Modified: 16 Feb 2017 10:03
    URI: http://eprints.cmfri.org.in/id/eprint/11559

    Actions (login required)

    View Item View Item